Hikma Pharmaceuticals PLC
LSE:HIK
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 767.5
2 083
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC
Total Receivables
Hikma Pharmaceuticals PLC
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Total Receivables
$965m
|
CAGR 3-Years
7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Total Receivables
£7.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
2%
|
CAGR 10-Years
4%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Total Receivables
$12.6B
|
CAGR 3-Years
23%
|
CAGR 5-Years
18%
|
CAGR 10-Years
4%
|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Total Receivables
$12.5m
|
CAGR 3-Years
6%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Indivior PLC
LSE:INDV
|
Total Receivables
$281m
|
CAGR 3-Years
16%
|
CAGR 5-Years
6%
|
CAGR 10-Years
4%
|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Total Receivables
£176.2m
|
CAGR 3-Years
21%
|
CAGR 5-Years
17%
|
CAGR 10-Years
20%
|
|
Hikma Pharmaceuticals PLC
Glance View
Hikma Pharmaceuticals PLC, a Jordanian-British multinational, began its journey in the heart of Amman, Jordan, in 1978, founded by Samih Darwazah. Over the years, it has evolved from a local pharmaceutical manufacturer into a global powerhouse, recognized as a key player in the generic pharmaceutical industry. The company's core strategy revolves around the production and distribution of a wide array of generic medications, serving diverse therapeutic categories such as cardiovascular, oncology, and infectious diseases. Hikma's competitive edge lies in its ability to produce high-quality and cost-effective medicines, which are crucial in both high-demand regions and emerging markets where affordable healthcare options are often limited. By leveraging its robust manufacturing capabilities and regulatory expertise, Hikma efficiently supplies generic and branded medications to over 50 countries worldwide, nurturing its growth and bolstering its market position. Driving the gears of Hikma's revenue machine are its three main operational segments: Injectables, Generics, and Branded pharmaceuticals. The Injectables division, a significant contributor to its financial health, supplies hospitals with critical sterile products, benefiting especially when acute care needs surge. Meanwhile, the Generics division continues to expand its footprint in the U.S. market, offering cost-effective alternatives to brand-name drugs, riding the wave of patent expirations. The Branded segment, deeply rooted in the Middle East and North Africa, capitalizes on Hikma's regional expertise and trusted brand reputation. Through this diversified business model, Hikma not only fortifies its financial stability but also ensures resilience against market fluctuations, steering the firm towards sustainable growth amidst an ever-evolving global pharmaceutical landscape.
See Also
What is Hikma Pharmaceuticals PLC's Total Receivables?
Total Receivables
965m
USD
Based on the financial report for Jun 30, 2024, Hikma Pharmaceuticals PLC's Total Receivables amounts to 965m USD.
What is Hikma Pharmaceuticals PLC's Total Receivables growth rate?
Total Receivables CAGR 10Y
10%
Over the last year, the Total Receivables growth was 7%. The average annual Total Receivables growth rates for Hikma Pharmaceuticals PLC have been 7% over the past three years , 7% over the past five years , and 10% over the past ten years .
You don't have any saved screeners yet
